Oxford Medical Products is developing a gastroretentive hydrogel platform technology, named Sirona, which is currently undergoing human clinical trials as a weight-loss treatment. This technology addresses the challenge of sustainable weight management by providing a safe and effective method for prolonged gastric retention, enhancing satiety and reducing caloric intake.
Funding
$5.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SVFounders
Product
Problem
Obesity and the need for sustainable weight management solutions remain significant challenges. Current weight-loss methods often struggle with long-term adherence and can be invasive or have undesirable side effects.
Solution
Oxford Medical Products is developing Sirona, a gastroretentive hydrogel platform technology designed for non-invasive weight loss. This platform utilizes a hydrogel that resides in the stomach for an extended period, promoting satiety and reducing caloric intake. By prolonging gastric retention, Sirona aims to provide a more sustainable and manageable approach to weight loss. The hydrogel technology also has potential applications in drug and nutraceutical delivery, and biosensors.
Target Audience
The primary target audience includes individuals seeking a non-invasive and sustainable weight-loss solution, as well as pharmaceutical companies interested in novel drug delivery systems.
Features
- Gastroretentive hydrogel that expands in the stomach to induce satiety
- Non-invasive weight-loss approach
- Prolonged gastric retention for sustained effect
- Potential applications in drug delivery for both small molecules and biologics
- Currently undergoing human clinical trials